Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Respiratory Syncytial Virus (RSV) is one of the most common reasons for young infants to be admitted to hospital, and globally is second only to malaria as a cause of death in infants between 1 and 12 months of age. In the UK it mostly occurs from October to February, causing a wave of infections that stretch the capacity of children’s wards to their limits.

At the Oxford Vaccine Group we are undertaking a number of projects that try to better understand the burden of RSV disease, and looking at several approaches to vaccine prevention.

This report by BBC South today looks at the impact that an RSV infection could have on an otherwise healthy infant, and a study being conducted by the Oxford Vaccine Group and OSPREA that looks to reduce infant RSV infections by maternal immunisation.

Similar stories

Oxford vaccine researchers talk research and home-schooling on ITV's This Morning

COVID-19 Public Engagement

Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

Award for OVG's learning games

Awards & Appointments Public Engagement

Learning games explaining the links between typhoid, sewage systems and food hygiene have won the gold prize at the Learning Technologies Awards 2020.

SIMON Says…

Publication Research

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Trial of Oxford COVID-19 vaccine in South Africa begins

COVID-19 Research

Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.